AllerGene AI Therapeutics
AllerGene proposes in vivo-delivered mRNA CAR-T to target mast cells in allergic disease. Its website establishes research intent, but does not establish a named clinical candidate, patient dosing, or validated allergy outcomes. It is distinct from Allogene Therapeutics.
Corporate information
- Company entity
- AllerGene AI Therapeutics
- Headquarters / principal office
- Miami, Florida, United States ↗
- Founded
- 2024 ↗
- Ownership / capital status
- PrivatePrivately held (company self-description) ↗
- Official corporate reference
- https://allergene.ai/ ↗
- LinkedIn company page
- LinkedIn ↗ ↗
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Start with public sources and capability boundaries; company claims are not independent certification.
Ask AI ↗Public evidence snapshot
AllerGene proposes in vivo-delivered mRNA CAR-T to target mast cells in allergic disease. Its website establishes research intent, but does not establish a named clinical candidate, patient dosing, or validated allergy outcomes. It is distinct from Allogene Therapeutics.
This profile is a research snapshot, not a company endorsement. Check original sources for current information.
Original sources
- AllerGene AI Therapeutics — primary program / ownership disclosure
- AllerGene self-published company LinkedIn profile (founded, location and ownership)